<SEC-DOCUMENT>0001104659-24-119469.txt : 20241115
<SEC-HEADER>0001104659-24-119469.hdr.sgml : 20241115
<ACCEPTANCE-DATETIME>20241115060520
ACCESSION NUMBER:		0001104659-24-119469
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20241113
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241115
DATE AS OF CHANGE:		20241115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		241465739

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2428551d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:cycc="http://cyclacel.com/20241113">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_cycc_cyclacel.com_20241113 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20241113_20241113 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001130166 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000004" name="dei:EntityCentralIndexKey">0001130166</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cycc-20241113.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-13</xbrli:startDate>
        <xbrli:endDate>2024-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-132024-11-13_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-13</xbrli:startDate>
        <xbrli:endDate>2024-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-132024-11-13_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-13</xbrli:startDate>
        <xbrli:endDate>2024-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="text-align: center; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20241113__20241113_zVtyCTIOMpC2"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of
earliest event reported): <span id="xdx_901_edei--DocumentPeriodEndDate_c20241113__20241113_zzMCiMzlBph8"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">November 13, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 14pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20241113__20241113_zScVK3R9txOe"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000012" name="dei:EntityRegistrantName">CYCLACEL
PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20241113__20241113_znhctxvdhNSf"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20241113__20241113_z4L2LIpEojea"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000014" name="dei:EntityFileNumber">0-50626</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20241113__20241113_z2VkSamuwbHe"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000015" name="dei:EntityTaxIdentificationNumber">91-1707622</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State
                                            or other jurisdiction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of incorporation)</p></td>
    <td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS
                                            Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20241113__20241113_zquT5VyfeoLf"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000016" name="dei:EntityAddressAddressLine1">200 Connell Drive</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20241113__20241113_zaG9j4w4Vn45"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite 1500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20241113__20241113_zQbtfN7WEKA6"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000018" name="dei:EntityAddressCityOrTown">Berkeley Heights</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20241113__20241113_zZUeDU5SlVGi"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000019" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20241113__20241113_zgg6EpAI1m53"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000020" name="dei:EntityAddressPostalZipCode">07922</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive
offices and zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b> (<span id="xdx_902_edei--CityAreaCode_c20241113__20241113_zBVFDyjsNsKl"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000021" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20241113__20241113_zMZe3RAYPhK"><ix:nonNumeric contextRef="AsOf2024-11-13" id="Fact000022" name="dei:LocalPhoneNumber">517-7330</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20241113__20241113_zv2E0R9JRsce"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20241113__20241113_zvlvvkpQMsWe"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20241113__20241113_z64ifsOqlNS3"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20241113__20241113_zeT6JQJlzlsj"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 40%"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 20%"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 40%"><span style="font-size: 10pt">Name of each exchange on which registered </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMSc8OUddit9"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zxx46IY7oAEg"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember" id="Fact000028" name="dei:TradingSymbol">CYCC</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90D_edei--SecurityExchangeName_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z5WJpQoUrDNc"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zL1YtESAe0ii"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember" id="Fact000030" name="dei:Security12bTitle">Preferred Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zNNXSzp59Gye"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember" id="Fact000031" name="dei:TradingSymbol">CYCCP</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_901_edei--SecurityExchangeName_c20241113__20241113__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zfJe7ZnTgBV9"><ix:nonNumeric contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging Growth Company&#160;&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20241113__20241113_zSWbwLxUmpt9"><ix:nonNumeric contextRef="AsOf2024-11-13" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2024, Cyclacel Pharmaceuticals,
Inc. (the &#8220;Company&#8221;) entered into a letter agreement (the &#8220;Warrant Exercise and Reload Agreement&#8221;) with the holder
(the &#8220;Holder&#8221;) of its issued and outstanding Series B Warrants (the &#8220;Prior Warrants&#8221;) to purchase an aggregate
of 4,968,945 shares of common stock of the Company, par value $0.001 per share (the &#8220;Common Stock&#8221;), offering the Holder the
opportunity to exercise all of its Prior Warrants for cash at a reduced exercise price equal to $0.415 per share provided the Prior Warrants
were exercised in full for cash on or before 12:30 P.M. Eastern Time on the date of the Warrant Exercise and Reload Agreement. In consideration
for the exercise of the Prior Warrants, the Holder received new unregistered Series C Warrants (the &#8220;Series C Warrants&#8221;) exercisable
for up to an aggregate of 9,937,890 shares of Common Stock (the &#8220;Series C Warrant Shares&#8221;) and new unregistered Series D Warrants
(the &#8220;Series D Warrants&#8221; and, together with the Series C Warrants, the &#8220;New Warrants&#8221;) exercisable for up to an
aggregate of 9,937,890 shares of Common Stock (the &#8220;Series D Warrant Shares&#8221; and, together with the Series C Warrant Shares,
the &#8220;New Warrant Shares&#8221;). The Series C Warrants are exercisable beginning on the date upon which the Company receives stockholder
approval of the issuance of the New Warrant Shares and the PA Warrant Shares (as defined below) (the &#8220;Stockholder Approval Date&#8221;)
for a period of five and one-half (5.5) years following the Stockholder Approval Date and the Series D Warrants are exercisable beginning
on the Stockholder Approval Date for a period of eighteen (18) months following the Stockholder Approval Date. The New Warrants each have
an exercise price of $0.415 per share. The shares of Common Stock issued upon exercise of the Prior Warrants are registered pursuant to
an effective registration statement on Form S-1 (No. 333-279157).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to file a registration
statement providing for the resale of the New Warrant Shares issuable upon the exercise of the New Warrants (the &#8220;Resale Registration
Statement&#8221;) as soon as practicable after (and in any event within thirty (30) calendar days of) the date of the Warrant
Exercise and Reload Agreement, and to use commercially reasonable efforts to cause such Resale Registration Statement to become effective
within forty-five (45) calendar days of the date of the Warrant Exercise and Reload Agreement (or within ninety (90) calendar days following
the date of the Warrant Exercise and Reload Agreement in case of &#8220;full review&#8221; of such registration statement by the Securities
and Exchange Commission (the &#8220;SEC&#8221;)) and to keep the Resale Registration Statement effective at all times until no holder
of the New Warrants owns any New Warrants or New Warrant Shares. Pursuant to the Warrant Exercise and Reload Agreement, the Company agreed
not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock equivalents
or file any registration statement or any amendment or supplement to any existing registration statement (in each case, subject to certain
exceptions) until sixty (60) calendar days after the closing of the offering. The Company also agreed not to effect or agree to effect
any Variable Rate Transaction (as defined in the Warrant Exercise and Reload Agreement) until one (1) year after the closing of the offering
(subject to an exception described in the Warrant Exercise and Reload Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from the exercise
of the Prior Warrants were approximately $2.1 million, prior to deducting placement agent&#8217;s fees and other offering expenses payable
by the Company. The closing of the offering occurred on November 14, 2024. The Company intends to use the net proceeds from this transaction
for working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;)
acted as the exclusive placement agent for the offering pursuant to an engagement agreement between the Company and Wainwright dated as
of April 29, 2024 (as amended). As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate
cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross
proceeds received by the Company from the offering, and reimbursement for accountable expenses of $25,000. The Company has also issued
to Wainwright or its designees warrants to purchase up to an aggregate of 298,137 shares of Common Stock (the &#8220;PA Warrants&#8221;
and the shares of Common Stock issuable upon exercise of the PA Warrants, the &#8220;PA Warrant Shares&#8221;). The PA Warrants are exercisable,
beginning on the Stockholder Approval Date for a period of five and one-half (5.5) years following the Stockholder Approval Date, and
have an exercise price of $0.5188 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The New Warrants, PA Warrants, New Warrant Shares
and PA Warrant Shares were sold and issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule
506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state
laws. Such securities may not be offered or sold in the United States absent registration or an exemption from registration under the
Securities Act and any applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form 8-K nor any
exhibit attached hereto is an offer to sell or the solicitation of an offer to buy the Company&#8217;s securities nor shall there be any
sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summaries of the Series C Warrants, the Series D Warrants,
the PA Warrants, and the Warrant Exercise and Reload Agreement do not purport to be complete and are subject to, and qualified in their
entirety by reference to, the forms of such documents, which are incorporated herein by reference to Exhibits 4.1, 4.2, 4.3, and 10.1,
respectively, to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Form 8-K, the disclosures in Item 1.01 above
are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.03 Material Modifications to Rights of Security Holders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Form 8-K, the disclosures in Item 1.01 above
are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2024, the Company issued a press release announcing
the closing of the offering, which has been filed as Exhibit 99.1 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%; padding-right: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-1.htm"><span style="font-size: 10pt">4.1</span></a></td>
    <td style="width: 88%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-1.htm"><span style="font-size: 10pt">Form of Series C Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-2.htm"><span style="font-size: 10pt">4.2</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-2.htm"><span style="font-size: 10pt">Form of Series D Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-3.htm"><span style="font-size: 10pt">4.3</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex4-3.htm"><span style="font-size: 10pt">Form of Placement Agent Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Warrant Exercise and Reload Agreement, dated November 13, 2024</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex99-1.htm"><span style="font-size: 10pt">99.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><a href="tm2428551d1_ex99-1.htm"><span style="font-size: 10pt">Press Release announcing closing of exercise of warrants for $2.1 million gross proceeds, dated November 14, 2024</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Date: November 15, 2024</span></td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt"><b>Cyclacel Pharmaceuticals, Inc</b></td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 47%"> <span style="font-size: 10pt">/s/ Paul McBarron</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Paul McBarron</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2428551d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES C COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">Issue Date:______, 2024</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES C COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Stockholder Approval Date (as defined herein) (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on the date that is the five and one-half (5.5) year anniversary of the Stockholder Approval Date, provided that, if such date
is not a Trading Day (as defined herein), the immediately following Trading Day (such Trading Day, &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock
(as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to
remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar
orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers
on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stoc</U>k&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Letter Agreement</U>&rdquo;
means that certain letter agreement between the initial Holder hereof and the Company, dated as of [ ], 2024, pursuant to which such initial
Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company agreed to issue to the initial Holder
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval</U>&rdquo;
means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity)
from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval
Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company required to be listed pursuant to Item 601(b)(21) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Equiniti Trust Company, LLC, the current transfer agent of the Company, the current transfer agent of the Company, with a mailing
address of 1110 Centre Pointe Curve, Mendota Heights, MN 55120, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$[ ]</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX
Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market operated by the OTC Markets, Inc. (the &ldquo;<U>Pink
Market</U>&rdquo;) (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading Days comprising the
Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by the earlier of (i) one (1) Trading Day after the delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading
Days comprising the Standard Settlement Period, in each case, after the delivery to the Company of the Notice of Exercise. If the Company
fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such
exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to
$20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%/9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or
any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of the assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50%
of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
 &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental
Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from
the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction
is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to
receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes
Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated
Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) the sum of the remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. As applicable, the payment of the cash portion
of the Black Scholes Value will be made by wire transfer of immediately available funds within the later of (i) five Business Days of
the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant and the Letter Agreement in accordance with the provisions of this Section 3(d)
pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the Letter Agreement referring to the &ldquo;Company&rdquo; shall refer instead to each of
the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly
and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the Letter Agreement with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least five (5) calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d)
hereof and to the provisions of the Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current
public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder
or transferee of this Warrant, as the case may be, provide to the Company an opinion of counsel in form and substance reasonably satisfactory
to the Company to the effect that the transfer of this Warrant does not require registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or
the Holder or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and, by accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to it at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any
provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact
that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the
Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 Attention: [ ], email address:
[ ], or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices
or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail,
or sent by a nationally recognized overnight courier service addressed to the Holder at the e-mail address or address of the Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided by the Company hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Cyclacel Pharmaceuticals,
    Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;<B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#9;<B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Phone
    Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Email
    Address: </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>tm2428551d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES D COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">&nbsp;Issue Date:______, 2024</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES D COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Stockholder Approval Date (as defined herein) (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on the date that is the eighteen (18) month anniversary of the Stockholder Approval Date, provided that, if such date is not
a Trading Day (as defined herein), the immediately following Trading Day (such Trading Day, &ldquo;<U>Termination Date</U>&rdquo;) but
not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock
(as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to
remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar
orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers
on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stoc</U>k&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Letter Agreement</U>&rdquo;
means that certain letter agreement between the initial Holder hereof and the Company, dated as of [ ], 2024, pursuant to which such initial
Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company agreed to issue to the initial Holder
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval</U>&rdquo;
means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity)
from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval
Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company required to be listed pursuant to Item 601(b)(21) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Equiniti Trust Company, LLC, the current transfer agent of the Company, the current transfer agent of the Company, with a mailing
address of 1110 Centre Pointe Curve, Mendota Heights, MN 55120, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$[ ]</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX
Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market operated by the OTC Markets, Inc. (the &ldquo;<U>Pink
Market</U>&rdquo;) (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading Days comprising the
Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by the earlier of (i) one (1) Trading Day after the delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading
Days comprising the Standard Settlement Period, in each case, after the delivery to the Company of the Notice of Exercise. If the Company
fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such
exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to
$20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%/9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or
any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of the assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50%
of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
 &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental
Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from
the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction
is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to
receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes
Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated
Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) the sum of the remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. As applicable, the payment of the cash portion
of the Black Scholes Value will be made by wire transfer of immediately available funds within the later of (i) five Business Days of
the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant and the Letter Agreement in accordance with the provisions of this Section 3(d)
pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the Letter Agreement referring to the &ldquo;Company&rdquo; shall refer instead to each of
the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly
and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the Letter Agreement with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least five (5) calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d)
hereof and to the provisions of the Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current
public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder
or transferee of this Warrant, as the case may be, provide to the Company an opinion of counsel in form and substance reasonably satisfactory
to the Company to the effect that the transfer of this Warrant does not require registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or
the Holder or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and, by accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to it at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any
provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact
that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the
Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 Attention: [ ], email address: [ ], or
such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent
by a nationally recognized overnight courier service addressed to the Holder at the e-mail address or address of the Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided by the Company hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Cyclacel Pharmaceuticals,
    Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;<B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#9;<B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Phone
    Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Email
    Address: </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>tm2428551d1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">Issue Date: November 14, 2024</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PLACEMENT AGENT COMMON
STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Stockholder Approval Date (as defined herein) (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on the date that is the five and one-half (5.5) year anniversary of the Stockholder Approval Date, provided that, if such date
is not a Trading Day (as defined herein), the immediately following Trading Day (such Trading Day, the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock
(as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b). This Warrant is being issued pursuant to that certain Engagement Letter, by and between the Company and H.C. Wainwright
 &amp; Co., LLC, dated as of April 29, 2024, as amended on April 29, 2024 and October 29, 2024 (the &ldquo;<U>Engagement Letter</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to
remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar
orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers
on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stoc</U>k&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval</U>&rdquo;
means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity)
from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval
Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company required to be listed pursuant to Item 601(b)(21) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Equiniti Trust Company, LLC, the current transfer agent of the Company, the current transfer agent of the Company, with a mailing
address of 1110 Centre Pointe Curve, Mendota Heights, MN 55120, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Engagement Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.5188</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX
Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market operated by the OTC Markets, Inc. (the &ldquo;<U>Pink
Market</U>&rdquo;) (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading Days comprising the
Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by the earlier of (i) one (1) Trading Day after the delivery of the aggregate Exercise Price to the Company and (ii) the number of Trading
Days comprising the Standard Settlement Period, in each case, after the delivery to the Company of the Notice of Exercise. If the Company
fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such
exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to
$20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or
any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of the assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50%
of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
 &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental
Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from
the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction
is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to
receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes
Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated
Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) the sum of the remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. As applicable, the payment of the cash portion
of the Black Scholes Value will be made by wire transfer of immediately available funds within the later of (i) five Business Days of
the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities,
jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right
and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company
prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least five (5) calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d)
hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current
public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder
or transferee of this Warrant, as the case may be, provide to the Company an opinion of counsel in form and substance reasonably satisfactory
to the Company to the effect that the transfer of this Warrant does not require registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or
the Holder or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and, by accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to it at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any
provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact
that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the
Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 Attention: [ ], email address: [ ], or
such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent
by a nationally recognized overnight courier service addressed to the Holder at the e-mail address or address of the Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided by the Company hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Cyclacel Pharmaceuticals,
    Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;<B>Cyclacel
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#9;<B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Phone
    Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black"><FONT STYLE="text-decoration: double">Email
    Address: </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: black">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s
    Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 30pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>tm2428551d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: right">November&nbsp;13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder of Warrants Issued in May&nbsp;2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement Offer to Exercise Warrants Issued in May&nbsp;2024</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cyclacel Pharmaceuticals,&nbsp;Inc.
(the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo; or similar terminology)
the opportunity to receive new warrants to purchase shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;) and in consideration for exercising for cash all of the Company&rsquo;s Series&nbsp;B warrants to purchase an aggregate
of 4,968,945 shares of Common Stock, issued to you on May&nbsp;2, 2024, with an exercise price of $1.36 per share and termination date
of November&nbsp;3, 2025 (the &ldquo;<U>Existing Warrants</U>&rdquo;), as set forth on the signature page&nbsp;hereto. The resale of the
shares of Common Stock underlying the Existing Warrants (the &ldquo;<U>Warrant Shares</U>&rdquo;) has been registered pursuant to the
registration statement on Form&nbsp;S-1 (File No.&nbsp;333-279157) (the &ldquo;<U>Registration Statement</U>&rdquo;). The Registration
Statement is currently effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for
the resale of the Warrant Shares, as applicable. Capitalized terms not otherwise defined herein shall have the meanings set forth in the
New Warrants (as defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company desires to reduce
the Exercise Price of the Existing Warrants to $0.415 per share (the &ldquo;<U>Reduced Exercise Price</U>&rdquo;). In consideration for
exercising in full all of the Existing Warrants held by the Holder as set forth on the Holder&rsquo;s signature page&nbsp;hereto at the
stated Exercise Price (the &ldquo;<U>Warrant Exercise</U>&rdquo;) on or before the Execution Time (as defined below), the Company hereby
offers to sell and issue you:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) new
unregistered Common Stock purchase warrants (the &ldquo;<U>Series&nbsp;C Warrants</U>&rdquo;) pursuant to Section&nbsp;4(a)(2)&nbsp;of
the Securities Act of 1933, as amended (&ldquo;<U>Securities Act</U>&rdquo;), to purchase up to 9,937,890 shares of Common Stock (the
 &ldquo;<U>Series&nbsp;C Warrant Shares</U>&rdquo;), which Series&nbsp;C Warrants shall </FONT>have an exercise price per share equal to
$0.415, subject to adjustment as provided in the Series&nbsp;C Warrants, will be exercisable at any time on or after the Stockholder Approval
Date and expire five and one-half (5.5) years from the Stockholder Approval Date, which Series&nbsp;C Warrants shall be substantially
in the form as set forth in&nbsp;<U>Exhibit&nbsp;A-1</U>&nbsp;hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">(b) new
unregistered Common Stock purchase warrants (the &ldquo;<U>Series&nbsp;D Warrants</U>&rdquo; and together with the Series&nbsp;C Warrants,
the &ldquo;<U>New Warrants</U>&rdquo;) pursuant to Section&nbsp;4(a)(2)&nbsp;of the Securities Act, to purchase up to 9,937,890 shares
of Common Stock (the &ldquo;<U>Series&nbsp;D Warrant Shares</U>&rdquo; and together with the Series&nbsp;C Warrant Shares, the &ldquo;<U>Warrant
Shares</U>&rdquo;), which Series&nbsp;D Warrants shall have an exercise price per share equal to $0.415, subject to adjustment as provided
in the Series&nbsp;D Warrants, will be exercisable at any time on or after the Stockholder Approval Date and expire eighteen (18) months
from the Stockholder Approval Date, which Series&nbsp;D Warrants shall be substantially in the form as set forth in <U>Exhibit&nbsp;A-2</U>
hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">(c) the
New Warrant certificate(s)&nbsp;will be delivered at Closing (as defined below), and such New Warrants, together with any underlying shares
of Common Stock issued upon exercise of the New Warrants, will, unless and until registered, contain customary restrictive legends and
other language typical for an unregistered warrant and unregistered shares. Notwithstanding anything herein to the contrary, in the event
that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo;) set forth in Section&nbsp;2(e)&nbsp;of the Existing Warrants (or, if applicable and at the Holder&rsquo;s election,
9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum
number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the
Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through
the Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant
to a Notice of Exercise in the Existing Warrants (provided no additional exercise price shall be due and payable). The parties hereby
agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants is as set forth on the Holder&rsquo;s signature page&nbsp;hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expressly subject to the paragraph
immediately following this paragraph below, Holder may accept this offer by signing this letter agreement below, with such acceptance
constituting Holder&rsquo;s exercise in full of the Existing Warrants for an aggregate exercise price and the Aggregate New Warrant Consideration
set forth on the Holder&rsquo;s signature page&nbsp;hereto on or before 12:30 p.m., Eastern Time, on November&nbsp;13, 2024 (the &ldquo;<U>Execution
Time</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the Company
agrees to the representations, warranties and covenants set forth on&nbsp;<U>Annex A</U>&nbsp;attached hereto. Holder represents and warrants
that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule&nbsp;501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain restrictive
legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered
under the Securities Act, except as provided in&nbsp;<U>Annex A</U>&nbsp;attached hereto. Also, Holder represents and warrants that it
is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not limiting
Holder&rsquo;s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder understands that
the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of
any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&ldquo;THIS SECURITY
HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED
OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certificates evidencing the
New Warrant Shares shall not contain any legend (including the legend set forth above), (i)&nbsp;while a registration statement covering
the resale of such New Warrant Shares is effective under the Securities Act, (ii)&nbsp;following any sale of such New Warrant Shares pursuant
to Rule&nbsp;144 under the Securities Act, (iii)&nbsp;if such New Warrant Shares are eligible for sale under Rule&nbsp;144 (assuming cashless
exercise of the New Warrants), without the requirement for the Company to be in compliance with the current public information required
under Rule&nbsp;144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv)&nbsp;if such New Warrant Shares
may be sold under Rule&nbsp;144 (assuming cashless exercise of the New Warrants) and the Company is then in compliance with the current
public information required under Rule&nbsp;144 as to such New Warrant Shares, or (v)&nbsp;if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;) and the earliest of clauses (i)&nbsp;through (v), the &ldquo;<U>Delegend Date</U>&rdquo;)).
The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date if required by the
Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which opinion shall
be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued
free of all legends. The Company agrees that following the Delegend Date or at such time as such legend is no longer required under this
Section, it will, no later than two (2)&nbsp;Trading Days following the delivery by the Holder to the Company or the Transfer Agent of
a certificate representing the New Warrant Shares issued with a restrictive legend, along with such certificate(s)&nbsp;or other documentation
reasonably requested by the Company&rsquo;s counsel and/or the Transfer Agent (within one (1)&nbsp;Trading Day following the delivery
by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares, which request shall include the
form of representation letter requested by this sentence), including a customary representation letter, in form and substance reasonably
acceptable to the Company&rsquo;s counsel and/or the Transfer Agent (such Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;),
deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends
or, at the request of the Holder shall credit the account of the Holder&rsquo;s prime broker with the Depository Trust Company System
as directed by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Holder&rsquo;s
other available remedies, the Company shall pay to a Holder, in cash, (i)&nbsp;as partial liquidated damages and not as a penalty, for
each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer
Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5)&nbsp;Trading Days
after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without
a legend and (ii)&nbsp;if the Company fails to (a)&nbsp;issue and deliver (or cause to be delivered) to the Holder by the Legend Removal
Date a certificate representing the New Warrant Shares that is free from all restrictive and other legends and (b)&nbsp;if after the Legend
Removal Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a
sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal
to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive
legend, then, an amount equal to the excess of the Holder&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any)
over the product of (A)&nbsp;such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal
Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B)&nbsp;the weighted
average price at which the Holder sold that number of shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this offer is
accepted and the transaction documents are executed by the Execution Time, then as promptly as possible following the Execution
Time, but in any event no later than 1:00 p.m., Eastern Time, on the Trading Day, the Company shall issue a press release disclosing
the material terms of the transactions contemplated hereby and shall file a Current Report on Form&nbsp;8-K with the Commission
disclosing all material terms of the transactions contemplated hereunder, including the filing with the Commission of this letter
agreement as an exhibit thereto within the time required by the Exchange Act. From and after the dissemination of such press
release, the Company represents to you that it shall have publicly disclosed all material, nonpublic information delivered to you
by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated
hereunder. In addition, effective upon the dissemination of such press release, the Company acknowledges and agrees that any and all
confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or
any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the
other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of this offer, the Warrant Shares
shall be issued free of any legends or restrictions on resale by Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No later than the first (1<SUP>st</SUP>)
Trading Day following the date hereof, the closing (&ldquo;<U>Closing</U>&rdquo;) shall occur at such location as the parties shall mutually
agree. Unless otherwise directed by H.C. Wainwright&nbsp;&amp; Co., LLC (the &ldquo;<U>Placement Agent</U>&rdquo;), settlement of the
Warrant Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date (as defined
below), the Company shall issue the Warrant Shares registered in the Holder&rsquo;s name and address provided to the Company in writing
and released by the Transfer Agent directly to the account(s)&nbsp;at the Placement Agent identified by the Holder; upon receipt of such
Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the Holder, and payment therefor shall
concurrently be made to the Company by the Placement Agent (or its clearing firm) by wire transfer to the Company). The date of the Closing
of the Warrant Exercise shall be referred to as the &ldquo;<U>Closing Date</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp; &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify">&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify">Spiro Rombotis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>President &amp; CEO</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Holder Signature Page&nbsp;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Holder: [ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Holder signature page&nbsp;to CYCC Inducement
Offer]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations,
Warranties and Covenants of the Company</U></FONT>. The Company hereby makes the following representations and warranties to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC Reports</U></FONT>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is not currently an issuer identified in Rule&nbsp;144(i)&nbsp;under the Securities Act.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization; Enforcement</U></FONT>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith, other than in connection with the Required Approvals. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Conflicts</U></FONT>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any &nbsp;liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration Obligations</U></FONT>. As soon as practicable (and in any event within thirty (30) calendar days of the date of this Agreement), the Company shall file a registration statement on Form&nbsp;S-3 (or other appropriate form, including on Form&nbsp;S-1, if the Company is not then S-3 eligible) providing for the resale of the New Warrant Shares by the holder of the New Warrants (the &ldquo;<U>Resale Registration Statement</U>&rdquo;). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement to become effective within forty-five (45) calendar days following the date hereof (or within ninety (90) calendar days following the date hereof in case of &ldquo;full review&rdquo; of such registration statement by the Commission) and to keep the Resale Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading Market</U></FONT>. Except for as related to the Stockholder Approval, the transactions contemplated under this letter agreement comply with all the rules&nbsp;and regulations of the Nasdaq Capital Market.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings, Consents and Approvals</U></FONT>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i)&nbsp;the filings required pursuant to this letter agreement, (ii)&nbsp;application(s)&nbsp;or notice to each applicable Trading Market for the issuance and sale of the New Warrants and New Warrant Shares and the listing of the New Warrant Shares for trading thereon in the time and manner required thereby, (iii)&nbsp;the filing of Form&nbsp;D with the Commission, (iv)&nbsp;Stockholder Approval; and (v)&nbsp;such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required&nbsp;&nbsp;Approvals</U>&rdquo;).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing of Common Stock</U></FONT>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the New Warrant Shares on such Trading Market and promptly secure the listing of all of the New Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. In addition, the Company shall hold an annual or special meeting of stockholders on or prior to the date that is ninety (90) days following the Closing Date for the purpose of obtaining Stockholder Approval, with the recommendation of the Company&rsquo;s Board of Directors that such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. If the Company does not obtain Stockholder Approval at the first meeting, the Company shall call a meeting every ninety (90) days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the New Warrants are no longer outstanding. The Company shall set the record date for Stockholder Approval prior to the Closing Date.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent Equity Sales</U></FONT>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;From the
date hereof until sixty (60) days after the Closing Date, the Company shall not (A)&nbsp;issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B)&nbsp;file any registration statement or any amendment
or supplement to any existing registration statement (other than (w)&nbsp;the Resale Registration Statement referred to herein or (x)&nbsp;a
registration statement on Form&nbsp;S-8 in connection with any employee benefit plan). Notwithstanding the foregoing, this Section&nbsp;(h)(i)&nbsp;shall
not apply in respect of an Exempt Issuance or (z)&nbsp;any prospectus or prospectus supplement in connection with the Warrant Exercise,
if required. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers,
directors or consultants of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for
services rendered to the Company, provided that such shares of Common Stock or options issued to consultants of the Company are issued
as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing
of any registration statement in connection therewith during the prohibition period in this Section&nbsp;(h)(i), (b)&nbsp;warrants to
the Placement Agent in connection with the transactions pursuant to this letter agreement (the &ldquo;<U>Placement Agent Warrants</U>&rdquo;)
and any shares of Common Stock upon exercise of the Placement Agent Warrants and the shares of Common Stock issuable upon the exercise
or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that such securities have not been amended
since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or
conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities,
and (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry
no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in this Section&nbsp;(h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person)
which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities. &ldquo;<U>Person</U>&rdquo; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any
kind, for purposes of this Section&nbsp;(h)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;From the
date hereof until one (1)&nbsp;year following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination of units thereof)
involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i)&nbsp;issues
or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional
shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other price that is based upon, and/or
varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or
equity securities or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some future date after the
initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, following the restrictive period set forth in Section&nbsp;(h)(i)&nbsp;above,
the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales
agent shall not be deemed a Variable Rate Transaction. The Holder shall be entitled to obtain injunctive relief against the Company to
preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form&nbsp;D; Blue Sky Filings</U></FONT>. If required, the Company agrees to timely file a Form&nbsp;D with respect to the New Warrants and New Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A-1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of New Series&nbsp;C Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A-2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of New Series&nbsp;D Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>tm2428551d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD>
  <TD STYLE="text-align: center; width: 50%; vertical-align: middle"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cyclacel Pharmaceuticals, Inc.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.95pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals ANNOUNCES CLOSING OF EXERCISE OF WARRANTS FOR $2.1 MILLION GROSS PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BERKELEY HEIGHTS, NJ, November 14, 2024 </B>--
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical company
developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of
certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36
per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued
upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co. acted as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the immediate exercise of
the existing warrants for cash, the Company issued new unregistered Series C warrants to purchase up to an aggregate of 9,937,890 shares
of common stock and new unregistered Series D warrants to purchase up to 9,937,890 shares of common stock. The new warrants have an exercise
price of $0.415 per share and will be exercisable commencing on the effective date of stockholder approval of the issuance of the shares
issuable upon the exercise of the new warrants (the &ldquo;Stockholder Approval&rdquo;). The new Series C warrants have a term of five
and one-half years from the Stockholder Approval, and the new Series D warrants have a term of eighteen months from the Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately
$2.1 million, prior to deducting placement agent&rsquo;s fees and other offering expenses payable by the Company. The Company intends
to use the net proceeds from the offering for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new warrants described above were offered
in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and/or Regulation
D promulgated thereunder and, along with the shares of common stock underlying the new warrants, have not been registered under the Securities
Act, or applicable state securities laws. Accordingly, the new warrants and shares of common stock underlying the new warrants may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement
with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon the exercise of the new warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Cyclacel Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel is a clinical-stage, biopharmaceutical
company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional
regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients
with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based
on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #272223">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #272223"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #2E2E2E">This news release
contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include, among other things, statements related to the intended use of proceeds from the offering and the receipt of Stockholder Approval.
Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials,
trials may have difficulty enrolling,&nbsp;Cyclacel&nbsp;may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further
clinical trials, development and commercialization of product candidates and Cyclacel&rsquo;s ability to regain and maintain compliance
with Nasdaq&rsquo;s continued listing requirements. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot;
 &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
 &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot;
 &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and
description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the&nbsp;Securities and Exchange Commission&nbsp;and are available at&nbsp;</FONT><FONT STYLE="color: #025186">www.sec.gov</FONT><FONT STYLE="color: #2E2E2E">.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #272223">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #2E2E2E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Company: Paul McBarron, (908) 517-7330, IR@cyclacel.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&copy; Copyright 2024 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! *T# 2(  A$! Q$!_\0
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MWDEX\*Z;'( [G/5F],#\*T?$GP_U#Q+X=T:QNO$L@U'3+H70U#[(I,CC.T[
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : CP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *QM5O;F+4[*T@G2!)PY:1D#8P
M/>MFLK4=*-]JME.ZQ/;PAQ(C\YR..* 'Z'?RZCIWG3!=ZR,FY1@/@]16E34C
M2) D:JB+P%48 IU &5KM[<64%M]G=4::=8BS+G .>:-)O;BXN;VVG9)1;.%6
M9%P&R.F/44[6M.DU**V2/9B.=9'#GJHSD4:/8SZ:L]LS(UL)"T!!^8 ]C0!I
MU1UFZELM(N;B$@21KE<C/>KU4M6M)+[2KBVB*AY%P"QXZT 1:-<RW5J99;V*
MY)QQ&H'EG&2#SUK2JAI4%S;VPAN8K=-@"J823NP,9/ YJ_0!G:Y?3:=I<EQ
MH+@A<D9"@GJ:ETR1Y;,2/>1W6XY62-=HQZ8J2]%R;9A:I"\A_AFSM([]*I:'
MIDFF6\PF9-\TAD*1_=3V% &K69KM_-IVF^="!N+JA=AD(#_$16G5:^%RUL1:
MQP2.3@K-G:1WZ4 )ISO)9J[W4=UN)(EC7:"/I5JLS0],DTNR>.5U+R2&0A/N
MKGL*TZ "BBB@ KGK_4KU=5O((;F*".VMQ,-R [CZ$YKH:Y[4?#\M_J-W<;D4
M/$HA;/*NIZGVH V-.N7O-.M[B2/RWD0,5]*LU%;>=]FC^TA?.VC?L/&?:I:
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5"C_;.G?\_<=700P!!R#R*6B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cycc-20241113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOFWbOdzZR+mYkxtmBzbXna7yUsaDGIRy3aO43WgcwF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:cycc="http://cyclacel.com/20241113" elementFormDefault="qualified" targetNamespace="http://cyclacel.com/20241113">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cyclacel.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241113_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241113_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20241113_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cycc-20241113_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cyclacel.com/role/Cover" xlink:href="cycc-20241113.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cycc-20241113_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cycc-20241113_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cyclacel.com/role/Cover" xlink:href="cycc-20241113.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiDocumentInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45222530271584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-50626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYCLACEL
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1707622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Connell Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berkeley Heights<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-7330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCCP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "I,&]9JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( *DP;UEED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "I,&]9)!Z;HJT   #X 0
M&@              @ %3$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "I,&]999!YDAD!  #/ P  $P              @ $X$P
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  ""%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2428551d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cycc-20241113.xsd</File>
    <File>cycc-20241113_def.xml</File>
    <File>cycc-20241113_lab.xml</File>
    <File>cycc-20241113_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2428551d1_8k.htm">tm2428551d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2428551d1_8k.htm": {
   "nsprefix": "cycc",
   "nsuri": "http://cyclacel.com/20241113",
   "dts": {
    "schema": {
     "local": [
      "cycc-20241113.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cycc-20241113_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cycc-20241113_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cycc-20241113_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2428551d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://cyclacel.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2428551d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2428551d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001104659-24-119469-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-119469-xbrl.zip
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M.C3L 5-0#KYN!!I>IJ:7?P%02P,$%     @ J3!O65.\ E+3"   P&D  !4
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M]-N00PJ<.9[,"*3S'A-(%PGJUAYI8(4.B?"]6Q'F:TRI>3*(6*<KX=#>(R$
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ME(I,DC"IMMUQLG*;R3F?R?@9)6M<DE0>Z)T\T.'?Y('^6&V^PDN23Y!4"C[
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M")U^AP!!(@BUHT*"=$D3QA]8XW&',[85'>#S&4OA&<I E%^H1E6AC59O2$2
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M6P?J\L]WR9TP18 %"6Z9[Z[?9=+N_IN:*!#H,=:Y**FDR&A#+$C8#UGKX4G
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MB!7\"R[_[\31Y_AS8(>*> KZ.?#IC%5A3;8Y</NO@/\GU\JUM$ "2KBTQ12
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MGPADMD1S7<\!2XQ-D[&S(&-J.7=( [R)E"*'E;=D8EH@D,1D()T^!0B-@N\
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M2L>W)-FSV)VUOBU=7&DX/^1-# E1DYO4M2IVA:_S8^6$:OJ4Z/@BV;I>^E<
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MS\$$A "^&XQI8*UFN;U_6&XW6T2>&PO7=%&D9IA8!D%#+PB(\FO6:=J&A>X
MD#),!CDKXH$C!>+XSX+CXJYD/"AMB=#2D*B6%1 DB9L(G#0&X9(/K *NS74@
M5_B@"\$M!%Z?YR#M,"& VE1:,5##D D!24Y=N ,A"&?BZ=ID#G"$*^(F8(\(
M$PBV[:A1)Y?5LRKI:]B0L;DDXR"<VI"'NN"_-Q*9*AG8F!@P@$Z\(%O A448
M*9^3\R7!+L=IZE&=@G8;/)"<V[%FD12@7K8 K=R-=$,LC@D]!VCN(EWCTH1@
MM<OMQD'YL%V/25-<$M8N1L2)@N&22)X\^$\B=F5,>9*&'^<" CDW(G,/U7$%
M7T%%.1M:IW6$('%"%+Z:$"?9A-@4=OE4N9"-08JZ57D$4UH:M$CV.8IC(+UM
M\SWP,8F>NV$C,F8< K%CPG1(6\=WYH/%",06+1M^5B#XO0HCYSR7\&[Z3BE6
M1^%;_/>2E(S6)=U@73Q@*$";RZX69%\ P02=(+>R-JU,-6M"2JUJ:X_@048L
MMI.?4SQO]A#@%?G+IV=!TC-_TC2H_'U%2FU24@[W"#]Q:6,(!;OC BT:RU/M
MEA8P_TT:3E@M;3+%##G2++T5%XOU9HH3)'O'!H<#'(3. Y,@M>;9,@OJK2B%
M_&V.444AI7.G2AJ-1D4]:"NM@[VO*'W='V]L\.+%(\4Y5S$-PRH##T@,M#H3
M/(! 2Y"J$)%*^#@4C<"# .LT:YWB<=U$,>6<S'(Z"1&*J]Y0S#V,PQ*6R2.;
M#K;!@:DUK%IH.H9FN)PVP4BKA&H$[A81%8>=H;$S$1#3@\B@U*CO@0NV*-8]
MP! M41#W\OQL8:V?+0N=%44:OL7+PP*+A49,8X[-P0)IA+"$X3!=PX%L#CJ3
M@2D),<6Q8PH3TDB6"Q(-G&Q9X1:GU&RMHO*PB(&4'"\@%!@6BH1JKQ JM!.%
MART"D^N:$ /)<!X4886*W@6>"FYR"N7H[GB9*F 7<*FP'!4[62-AT_N]0'SV
M J9]HM3E<ZWG161-,$H$<'VNC5A LXCM!-%XEF@[=S;C@IB\ZF5H397$#SS<
MF*3EA.L42EV0E4-N3\LB(9'I2# F$#(^! '2;-N9HS]-.E</]=]U> 0;\[@X
M3\)TP\#$;_XQ%10="*WPK4)N8KAOS[;'XLTW+?AJ UY@<]>U0D"Y-B_@6;1$
M.;.40+S$_B^0L3),,/X(C.-Z1SU?,^T"7>C4Y1LI]R3_F+E 4=]?$75A3) :
MNN4P'KH(!@?9AW!E(>4MY@0V59)?R W'#:]'EPKXP'L-DF@T#T/4HBNLZ6KB
MD,M2LLNSL2@$*.'KLR5%!!_WHU$HQ>C$?;@D$<# =,\<;PO%H_K/I_.5-Y[#
M>%%<!Y:R0"<#=D\\9Y;P;(7L.(5G@3QV79CX7@QXAG^K587,3,LR\5A@EX^'
MV0U,/KETNUAYX *MW=#8R]$3*H-:<0A3F 73A4MM!O=<;<DS*VDA):Q"3G.X
M3QP=S"B&4$Z\#M(4=9"DB(N775F\)P%^(B*1I(G)1(="2#,/E>\<[Q,NILMN
M+R(!J$%J:I'@$">*01Q:&O8="-"O>-CS![ X=[RD3G[69NX+(&2U3$Y/>Z04
MEG^"$6%FH?'6#U@ (5RZ-6?H>5(R$<9B(1_C31O48OL&!LH' GL_IOX=1OX)
MCP&LB &*+AV71W'N@FQ:1&T+6>!FB1MH:D#>UV6\XP2")ZSPA%MLL+UI2!GU
M;O$0BZ2C2D:@(+AQ(!+5)5XL =&/RC 'U?I/@1RGM#2L6"15(%+7@%Z@>$!9
MB'J!P0&A$HLHZ44*#UD$J>M1<S8&[LA%T!V(]IL(#@/EQ61);97K]7I2ZSBE
MT+F([ C?-(^1"F;#LA:8:A! M ]W@>6)E^NRRRQJ^["L- XVJ2U$*720^A>"
M9'5-+A?E "O97#>[5K*2JB<+#;''TBEQN;!28]@\)]Y)^LZY7<!4F.2EPBWE
M\#"6"__][=S]W2?U2;I/J9U:._FBPO?2NGHNLI(N'9635F U(^(F9K5XQT,J
MD!/1UI U(\Q<G;F?S QRW_:7.Z/*)')IJ5)J?'C8>"A '.Q1RQ194%C9F+GR
MU:R@&P!^(3BPOEG2]DIJN&DB!0<N'P^6>.9@VK>.=8OF!DS4?&R9>N3E>< ]
MAQ"O5=_']69SZX9[[%Q4L50">0WW!^!W(-(S?1[1WU+F.QX3/BJ%&#,A/H7D
M(8:</)[$Q4\M<;O.TZZ"I=U!YCI"Q\^BA6?@SQ&5L?2%&%YZ@F<RE7AG<S!X
MD@U$&#-Q*'V,>3PEC" 0WC6;O84TSK8ATLD4M'$0.>!_?P-\3DVYBQ#"[AY&
M\D!'>?9_4.3$(VMLD6%# CPUQR:0R/<A408.P,.4UP&0VIQ9*"D,#T"4(283
MIP"$Y];$QXWGB1 H3%5BA,:5P=UAV0370IE 0.(EQ-AH6;<3['*2)\WB3=$M
MX($F!Z*< *_,Q0QGOG/F%M;V04B TY.Y%25:B3HG7,*(+SK#,U*DE+ $90^^
M=B9\WX$X7?%SAX!"#M\;-I_!0R9ED?G*;'2M]"M$]RAAWH-P<;,ZH>%P^\$S
M0D]60\4.-RK[)!C^184+,;_D9%BP,+T"GL_J83%SC+4G^1U,_H X8LF;L;#>
M:,AO2@"T0LQPC>B48:DL,'5J+L"%*Q4CS:I2AC]4_*,A8%+J<*T ?LL5-41K
M61:UA+7ZNBM1VOU'O.2VD$:UKH(1C[=4N9<!6O8_S[$!']GD9[PG!"3>B397
MH@<"X#WAP@->"%$Q3(8EE+DGC%2T-T8;.]C\VD!4_@Y,;43;>\X<(S2+/'P8
M\I-.D<7!3G^Y4> ?#O]=.'R(^%SPB*&/K;'GS+E-]FLU@_U:\3I,L.D)7#Z>
MK0J!+15[EGB'(VA>Y11$ ]N/99<Q%LNP=<$+<M+*DW:[JOQ]37A>(B\%I(T"
M\CK8*!XUP43A.7!TNY2:?(!V?M)CSE+X,;$ LR<,X9[U*0[\Z/_T"W7!U/A)
M$ ECL&6\56UBW6-M'2;BK4;$E\S]F=I4#ULMQ5"NZ:)94:I3?W;?2W@09(7O
M FC9;_Y)0 \/<P$-KHI-\$\(/3</W(4F0^DT2IN]1KS*HT?AB[H97]3[^/)T
MO-@(XA0O3OX6O&ALQHO&\^'%1A 'O+@,VT==WCYZ_BQ1ZE+S@S7PE=D*3( [
MDXZ(K+C<AS_FB<^%9;O!:,/M*Z+CF/'AQF?+\'9[,U./@>)S8>FF,%_RD'FX
M$C+'P^5X,R]L-V)++;ZS(=697>5S\QGQ^1[-;*X[96#W'%P+30\(Z/$N&QE@
M6TL3.]-.-%\37Y(J(7T-0_9$9+G]CU?#T["^M?>XK]EO$ONN:1@V_FD8/J>&
M87%7R=?N:QJ/^5D$_+#\X,UY]^K=<#<?M[]OM:=*=M.;3&4]3.3XFYT-(:K[
MJ9?6C;FU%-N;#5$9$9^(D*5[OCN%[S'#,OF8\CT6<OL,[[C( 5A3F^-&53Z=
M-O>GC@=*:E2?4\X<NH#,;VK":+2N+XMJQC<WUWPE,N_S?CF' N7Y!]R)<A1S
MLZV4F\T!=7LHQIW<=R3!,^GAAP=W@O,]A/Z:^=;!)^6BA6_ ;_']U)QEHV^J
MWGMLXZOET=><;+0M0,T#@(BL!ZG&:N"KYQ8YTU]!T(<?_ES_^=.=,^V>R/49
MP]:;FG02*ZM>\.]Z>6OCL.?K<=<$;\T7Y$)L&#DBI_BAH.\AELN.K( 0M;%C
M+/'\9$BLK,[_ U!+ P04    " "I,&]9[F+\'D<I   YP0  %@   '1M,C0R
M.#4U,60Q7V5X,3 M,2YH=&WM?6E3&]>VZ'=5Z3_LYY>3$E4-!ALG\7!<)8-\
MS+L8>(!S7NK6^]!J;4''K6ZE![#RZ^^:]M1J">QC;.(X'V(D=>]A[35/^\6;
M\[>'+_N]%V]&PWWX5^%_+\X/S@]'+U\\Y'_AUX?R\XM7Q_N_J;/SWPY'_WPP
M+?+ZF=K9GM?J/)WI2AWI:W5:S.(\XB\B=:;+=/H 7H173\Q[M?Y0;\99>I$_
M4V5Z<5D_5[.XO$CAX_:#ER]>O1Q]N$S':0U#;^V\>/@*%G+2&L)[_L=\7,V?
M+S]RV]5YD\.CV\^5O[Q$Y[4N:5%[O^T=#O=&A^KDS?#T+?SU[OQ@;WAX%O$"
M#H[VMKK7^HD+^>P[H__O;CU)\W"/= 0/7AX55WHVUB7/NO,X4H^V'^W>W^V$
MF_B]J>ITNGCP\DV1372IBJGZ=UR6<5Y7ZJ"J&CU1::[>Q@M>Q=UN[7SXZG"D
M %<.STZ&>P='__KG@^T']/EDN+]O/G_TI-?II+[$1[?_\8!(]<7YJ1GE2I=U
MFL29@4==S!\(.;\XWS=/R0B[O\P_/%<X\6:5_JEY=D#RU\='Y_ZR-J?Q+,T6
MSVY:V-)(I_K9BX<X&O*0_>5UM%Y8<92?;STOWKT\R"=-HF= S^IX.@4,J0LU
M^J#+)*WT+5#EW4M_0_"_4SZ!AW36+^\.G[\,U>SKN%1,.L_^8B0O7Z;Y1..@
MV\C@'KS<6R19G.A,G5S&Y0S^:H@\*L.M\V2KWQO4EUK]F$W^:(KG@")[Q6P>
MYPL\[!]+^G)#I96:9SJN "D 80J#.8NB40/W)D/.>S'RAH5GO5]44:HJ!30&
M@(-HF:5YD147BXU^#Q=3S.=%63=Y6B]PFE(G.KW2*@?P7!L<A>_G39E<PJ)4
M!;L#\ &WP[=E S^6%<Y4J:28S8I<5761O(_4'&:\BK-&JQ^VM[:W=]0<]D(#
MJ&5 P'O]WAF^&( CSHDXDB*O4MAQ7*<P_A2VI)F4TOR"/B9Q=:GB+%NU,CQ=
M7?%9O.K>6IRK^.*BU!=QK?L]&&<W>OK3+]'3W2?>KGFEZHQWF#+UROD4/A&S
M-(N A]:7.+0VI#\OTT3C4#_L;#W^R8,);I4/B'<Y,>L(!27+R2=M$(X^I("=
M  W#6GPP1BJN5*5K!!4L!P;'ERO ZKAN8.IY?*%Y]$M=ZKK84N?P.VPYSK1
MM-_K!H)J@ [*;(%3XZ!+ZV@O5+Y79S1<<-AP#&JL=0XS7\ HL)0)'D_5X/,
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MN/AEFERJ;G (KQ6]GUCNLN+@6(7^HXDS6&^_QUPD4E4S_AT@AWN()X@=))X
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M!,?M/#RL,?)9[2!Q)4B(\2?%XD.E&.6(Q(FC- S,/\,'9O+P@,'(BG27(!H
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M=C<@WA]2*4IC5!U);8(YC$YF.2FE.MF(PXJ1?;\6.FUL@&]%J'/5\>/BK6U
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M41(@K5SGVW:6$"X?^7DDTIP2'58D$IV:V4WW7*K+ZP*TO9N#@-%.Y?.V*5+
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M!-1V1,<#?TU_9,'E>0(G !X4:'.!#3:,LH]XO)-Y1WX"J"CU'.B0B.;5>5[
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MN4=P-).RDII\.G+)]^6/R9(,-8 /!@9!/^9@HJ"K$E$I=24^C!(9>$8 X83
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M$_@.6&XI!KY+DA.W66-KA_O$8P4GN?ED$6*E*+JB[7<-Q-AKKT^RCY)* GF
M"R?=J:HB&<Z9(?(]EY"Z:4.D/A5BL2Q&FY.:6^27Y'!C\JTT.*!=<T7P[E(:
MUSO+RF.JI"8C RGTI"2)J2A04\QTF#-9@3K7?4<2HS[25D,<30%'/OB1(XI
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M[7JL',=GR*[=1!C#?;'2I^)TV]JS ;HCL'_A)H1Y\T*J3IY8*I8QRE2CR>.
MBQR*J"<F">)4['F*,7E$#GQR\W2M/#S<K<:47-<"Q1[=7XBD"6XQMM4[88M*
MH*6"KH+S.$K,V4<NX>E9HGZ$^9/NR3=SBY+](?L$K5<-N;WV&U?\HD600G/9
MQH_@J(I0%$4H15]VDQ?UK4JY(P% T"AJ'(H8.L8NN#9JVNPPD53^;3 @O4R5
M6U&VDB&TUTBUW8BJ:MI41XTK3+9AK4[AVH1H<5L8KY8T(ZB0=,Y3JR:IVQU
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MH1_19)*D:)F6VIV<FB-J]"OD*)]P0(6$K<OH7],8CW]\)1ABOH@%?X=%>^7
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M1>:[#Z"'_;5:T.VO]RSH]M>'H-N=6L39+3\DEA\;KV/*ZC@^_[E\@E6?S0[
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MKQ)[6750_S@Y_/EHY_3#\4&_]^Y5\/K=F_V#XW]^E4%^2X#5D1B7O%T0Q7N
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MH+U5>0[Z/=ZMN(?L@!N^!25,X,">2:X53^,HXT0GQJKD\E_UJ->5XN=;+=K
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M8N2&E\PT:LNYK7*K)1>ES\8X9NRH^7P8I:1@]=ND:/&-]F/25'FQZ/>\FL!
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M6ME/J.Y@S,[RR2Q-VBMM0^T&3+7C<!BF<2-ZX=A3SREJ/D-*H8AA!=Q"+\9
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M?7SR2DFN+2?U\R8JJX=,UPJ9KEM5;/C#[KO]WW C__#Z].V;[?\/4$L#!!0
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MR_:#-;SN+VG\KWG^RK_\+P5]. CQ'<)^;V=O[_W)_L'1SX>_A<&['13?&8@
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MBQ7=-,F^S!9K>^Z7?R*=;^T:KM]K5W'!6G6AM+WR^H->*:]_^+"M[158!+
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M8:C/!D.\1G_U>RWZ?*W,V0]D]S.+'0RJ.\KB1F(+.<M#/4ZH/8,Y'^1$=D8
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M/=H/N^_W?R.R@K=G[PZW_S]02P,$%     @ J3!O64(@R=GG#   :BX  !8
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M8V,M,C R-#$Q,3,N>'-D4$L! A0#%     @ J3!O65.\ E+3"   P&D  !4
M             ( !: ,  &-Y8V,M,C R-#$Q,3-?9&5F+GAM;%!+ 0(4 Q0
M   ( *DP;UD2YA9=J L  )./   5              "  6X,  !C>6-C+3(P
M,C0Q,3$S7VQA8BYX;6Q02P$"% ,4    " "I,&]9]TCC#2D(  !:9   %0
M            @ %)&   8WEC8RTR,#(T,3$Q,U]P<F4N>&UL4$L! A0#%
M  @ J3!O6>@U(R;Y&@  P9D  !(              ( !I2   '1M,C0R.#4U
M,60Q7SAK+FAT;5!+ 0(4 Q0    ( *DP;UGN8OP>1RD  #G!   6
M      "  <X[  !T;3(T,C@U-3%D,5]E>#$P+3$N:'1M4$L! A0#%     @
MJ3!O6??*5RHD40  <M8! !4              ( !264  '1M,C0R.#4U,60Q
M7V5X-"TQ+FAT;5!+ 0(4 Q0    ( *DP;UF[+5_E+5$  "+9 0 5
M      "  :"V  !T;3(T,C@U-3%D,5]E>#0M,BYH=&U02P$"% ,4    " "I
M,&]96\\;DY-0  "_S0$ %0              @ $ " $ =&TR-#(X-34Q9#%?
M97@T+3,N:'1M4$L! A0#%     @ J3!O64(@R=GG#   :BX  !8
M     ( !QE@! '1M,C0R.#4U,60Q7V5X.3DM,2YH=&U02P4&      H "@"9
) @  X64!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>tm2428551d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cycc-20241113.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="From2024-11-132024-11-13_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="From2024-11-132024-11-13_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-13" id="Fact000004">0001130166</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-13" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-13" id="Fact000011">2024-11-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-13" id="Fact000012">CYCLACEL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-13" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-13" id="Fact000014">0-50626</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-13" id="Fact000015">91-1707622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-13" id="Fact000016">200 Connell Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-13" id="Fact000017">Suite 1500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-13" id="Fact000018">Berkeley Heights</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-13" id="Fact000019">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-13" id="Fact000020">07922</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-13" id="Fact000021">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-13" id="Fact000022">517-7330</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-13" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-13" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-13" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-13" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember"
      id="Fact000027">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember"
      id="Fact000028">CYCC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-11-132024-11-13_us-gaap_CommonStockMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember"
      id="Fact000030">Preferred Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember"
      id="Fact000031">CYCCP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-11-132024-11-13_us-gaap_PreferredStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-13" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
